Aashish Verma v Union of India through Narcotics Control Bureau, Amritsar Zonal Unit, 2026
It highlights judicial caution in evaluating bail petitions in complex narcotics offences involving layered arrangements or intermediaries.
Judgement Details
Court
Punjab and Haryana High Court
Date of Decision
18 February 2026
Judges
Justice Sumeet Goel
Citation
Acts / Provisions
Facts of the Case
-
The case arose from a massive seizure of over 1.37 crore psychotropic tablets weighing 5772.584 kg, including Alprazolam, Tramadol, and Zolpidem Tartrate.
-
Eight connected regular bail petitions were filed by accused persons, including directors and proprietors of licensed pharmaceutical companies.
-
Petitioners argued:
-
They operated through licensed pharmaceutical entities.
-
No illegal sale had occurred; all transactions were to licensed distributors.
-
Investigation was complete, no further recovery was pending, and prolonged incarceration served no purpose.
-
Mandatory provisions of the NDPS Act for grant of bail were not complied with.
-
-
NCB countered:
-
Huge commercial quantity recovered.
-
Petitioners implicated via disclosure statements of co-accused and subsequent recoveries.
-
Some accused admitted to procuring and distributing psychotropic medicines through medical stores.
-
Section 37 NDPS Act bars bail for commercial quantity offences.
-
-
The High Court emphasized that commercial sophistication or licences cannot shield from criminal accountability, especially in cases of organised diversion into illicit channels.
Issues
-
Whether the petitioners are entitled to regular bail under Section 37 of the NDPS Act despite operating through licensed pharmaceutical entities?
-
Whether the existence of licences or corporate structures negates prima facie inferences of organised diversion of narcotics?
-
Whether commercial sophistication can serve as a defense against criminal accountability in large-scale narcotics cases?
-
Whether the magnitude of seized contraband and involvement of intermediaries justifies the rejection of bail?
-
Whether the court can examine legality of commercial transactions at the stage of regular bail?
Judgement
-
The Punjab and Haryana High Court dismissed all eight connected regular bail petitions.
-
It held that the rigours of Section 37 NDPS Act are clearly attracted due to the seizure of a commercial quantity of psychotropic substances.
-
The existence of licenses or corporate structures does not automatically negate prima facie allegations of organised diversion into illicit channels.
-
Commercial sophistication or layered business arrangements cannot shield accused from criminal accountability.
-
The Court noted that at the stage of regular bail, it would not undertake a meticulous examination of the legality of commercial transactions but cannot ignore the broader factual backdrop.
-
Observed that prima facie, petitioners were involved with firms existing only on paper, indicative of organised diversion.
-
The Court reaffirmed that discretion to grant bail is narrower in offences involving commercial quantities under the NDPS Act.
Held
-
All regular bail petitions dismissed.
-
Section 37 NDPS Act applies, barring grant of bail due to commercial quantity seizure.
-
Mere existence of licences or corporate structure does not protect from prima facie inferences of organised diversion.
-
Commercial sophistication is not a shield against criminal accountability.
-
Investigation completion or lack of direct recovery does not justify grant of bail in large-scale NDPS offences.
Analysis
-
Reinforces the principle that NDPS Act’s Section 37 imposes strict restrictions on bail for commercial quantity offences.
-
Emphasizes that organised diversion of regulated pharmaceuticals cannot be masked by licences or corporate structures.
-
Highlights judicial caution in evaluating bail petitions in complex narcotics offences involving layered arrangements or intermediaries.
-
Confirms that prima facie evidence of organised diversion suffices to deny bail, even if direct recovery from petitioners is not made.
-
Strengthens accountability of pharmaceutical companies and their directors in cases of narcotic substance diversion.
-
Affirms that discretionary power of bail is narrower where commercial quantity and organised crime are involved.